Dupixent COPD denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent copd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Dupixent for COPD as Not Medically Necessary

A medical-necessity denial from UnitedHealthcare means the plan's clinical reviewers concluded that the documentation submitted did not demonstrate that Dupixent (dupilumab) is medically required for your COPD — typically because the chart did not clearly establish the type-2 inflammatory endotype the drug targets, did not document adequate prior treatment with standard therapies, or did not show sufficient disease burden to justify a biologic. This is rarely a final answer; it is almost always a documentation gap that a well-constructed appeal can fill.

## Federal Appeal Rights

• ERISA §503 (employer-sponsored plans) guarantees a full-and-fair internal review with a written denial rationale. You are entitled to a copy of the specific clinical criteria applied.
• ACA §2719 provides an independent external review right if the internal appeal is denied — at no cost to you.
• Internal appeal deadline: generally 180 days from the denial notice.
• External review request: typically 4 months from the final internal denial.
• Expedited review (72-hour decision): available when delay would seriously jeopardize your health — request it in writing with prescriber support.

## What to Gather

1. Confirmed COPD diagnosis — spirometry records, clinical notes establishing severity, and exacerbation history with dates and outcomes (hospitalizations, ED visits, oral steroid courses). 2. Type-2 inflammatory phenotype evidence — eosinophil count(s) from blood work, any sputum or biopsy data, and your prescriber's clinical reasoning that your COPD has an eosinophilic or type-2 driven component. 3. Prior therapy history with outcomes — a dated list of every inhaled bronchodilator, inhaled corticosteroid combination, and other maintenance therapy tried, with start/stop dates and why each was insufficient (side effects, inadequate symptom control, continued exacerbations). 4. Prescriber medical-necessity letter — your pulmonologist or treating physician should state in writing (a) your diagnosis and endotype, (b) the inadequacy of standard therapies, (c) why dupilumab is the appropriate next step per the FDA-approved label and applicable guideline organization recommendations (e.g., GOLD, relevant pulmonology society), and (d) the expected clinical benefit for you specifically. 5. UHC's coverage criteria — obtain UnitedHealthcare's current dupilumab medical policy and map every listed criterion to a specific dated chart entry.

## Criteria-Mapping Structure

Your appeal letter should reproduce each UHC criterion and provide the corresponding evidence:

| UHC Criterion | Chart/Document Evidence | |---|---| | COPD diagnosis confirmed | Spirometry date, FEV1/FVC pattern, clinical diagnosis note | | Type-2 inflammatory endotype documented | Eosinophil result with date; prescriber's phenotyping note | | Prior standard therapy trialed and inadequate | Medication list with dates and documented outcomes | | Prescriber attestation of medical necessity | Letter citing FDA label indication and guideline org support |

Request the specific clinical criteria used in the denial in writing — you are entitled to them. A complete, criterion-by-criterion response dramatically improves reversal odds at both internal appeal and external IRO review.